CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase With Antitumor Activity in Experimental Models of Human Cancers
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-11-0776
Full Text
Open PDFAbstract
Available in full text
Date
December 27, 2011
Authors
Publisher
American Association for Cancer Research (AACR)